Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

You may be eligible if

• 1. Written informed consent
• 2. Previously untreated follicular NHL
• 3. Stage III or IV disease requiring treatment
• 4. Able to receive rituximab and chemotherapy (rituximab with cyclophosphamide, vincristine, and prednisone either with or without doxorubicin)
• 5. Able to provide tumor sample adequate for Id-KLH manufacture
• 6. ≥ 18 years of age
• 7. At least one bi-dimensionally measurable lesion ≥ 2 cm by CT scan